By Sarah Hof
Decentralized trials are here to stay, and major pharma companies have already bought into their effectiveness, as reported by FierceBiotech. While the operational component of decentralized or remote trials once posed a logistical hindrance, the pandemic has forced rapid advancements in the means to ensure an increasingly smooth experience for both patients and investigators.
A lesser-known boon to remote trials’ wider adoption was how during the spring of 2020 when the pandemic was nearing its height, the FDA issued an announcement urging sponsors to shift to remote operations wherever possible in trials in order to continue research.
Paul Kirchgraber, M.D., who is the CEO of Covance was quoted saying that “We anticipate that by the end of 2021, the majority of our new studies will include a decentralized component.”
Read the full article here.
